agilon health cuts 2023 medical margin guidance by ~$110M; withdraws 2026 outlook

agilon health, inc.

2023 medical margin guidance lowered to $340M-$360M from $455M-$470M, a ~$110M reduction.
2023 Adjusted EBITDA guidance revised to loss of $55M-$69M from prior profit of $6M-$18M.
Higher-than-expected medical costs from specialist visits, Part B drugs, outpatient surgeries cited.
Initial 2024 outlook: medical margin $560M-$600M; Adjusted EBITDA $40M-$60M.
Withdraws previously issued 2026 target; actions underway to improve predictability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.